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Abstract 
Introduction: This study translated and validated the Urdu version of the European Organization for Research and 
Treatment of Cancer Quality of Life (QoL) Questionnaire (EORTC QLQ-C30) and Brain Module (QLQ-BN20) amongst 
patients with primary brain tumors (PBT) in Pakistan, and assessed the correlation of QoL with resilience, depression, 
and anxiety.
Methods: Translation of the EORTC QLQ-C30 and QLQ-BN20 was performed as per EORTC guidelines. A survey com-
prising of Urdu translations of EORTC QLQ-C30, QLQ-BN20, Wagnild and Young Resilience Scale (RS-14) and Hospital 
Anxiety and Depression Scale was administered to patients with PBT at a tertiary care hospital in Pakistan. Reliability 
(via Cronbach alpha), content validity index (CVI) scores, construct validity, and inter-scale correlations were assessed.
Results: Our sample consisted of 250 patients with PBT, most commonly glioma (46.8%) and meningioma (21.2%). 
All patients were able to understand the Urdu translations. The Cronbach alphas for the QLQ-C30 and the QLQ-BN20 
were 0.860 and 0.880, respectively. The CVI scores for clarity and relevance were high for both the EORTC QLQ-C30 
(0.98 and 0.96, respectively) and the QLQ-BN20 tool (0.81 and 0.95, respectively). The global QoL domain (EORTC 
QLQ-C30) showed significant positive correlations with resilience (r = 0.422), and significant negative correlations with 
depression (r =  − 0.541) and anxiety (r =  − 0.502). Strong inter-scale correlations were observed between physical 
functioning and insomnia (r =  − 0.690) and role functioning and insomnia (r =  − 0.641).
Conclusion: Our study confirms the Urdu versions of the EORTC QLQ-C30 and QLQ-BN20 as valid clinical tools for 
the measurement of QoL in primary brain tumors patients within the cultural and socioeconomic context of Pakistan.
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Introduction
Malignant primary brain tumors (PBTs) are responsible 
for 2.7% of cancer deaths worldwide [1]. In the United 
States of America (USA), the incidence rate of PBTs is 
approximately 14.8/100,000/year, and morality rate is 
greater in males (5.6/100,000) as compared to females 
(3.7/100,000) [2]. In developing countries, however, both 
the incidence and mortality rates of PBTs is lower than 
those seen in developed countries [2]. In Pakistan, which 
is a lower-middle-income country (LMIC) in South Asia, 
malignant PBTs comprise around 3.6% of all malignan-
cies [3]. However, the levels of distress experienced by 
patients with malignant PBTs is higher than that expe-
rienced by patients suffering from most other types of 
malignancies [4].
Quality of life (QoL) is a broad, multi-faceted concept 
that encompasses functionality and well-being in the 
physical, emotional, and psychosocial domains [5]. It is 
an increasingly important outcome in clinical neuro-
oncology [5]. The vast majority of patients with PBTs face 
varying levels of physical, emotional, or cognitive dis-
tress. This distress may be attributed to factors such as 
physical disability, disfigurement, sensorimotor deficits, 
losses of individual freedoms, employment, and income, 
and social stigma [4]. Moreover, mental health outcomes, 
particularly depression, are strongly associated with 
poorer QoL in patients with PBTs [6]. Resilience, which 
is the capacity of individuals to maintain stable physi-
cal and cognitive functionality despite the many chal-
lenges of cancer, may help protect against adverse mental 
health outcomes and improve QoL in patients with PBTs 
[7–9]. Amongst the several tools designed to assess QoL 
amongst patients with PBT, the EORTC QLQ-C30 (Euro-
pean Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire) and its brain tumor-spe-
cific module EORTC QLQ-BN20 (EORTC QLQ-Brain 
Neoplasms 20) have proved to be brief, reliable, and valid 
assessment measures [10, 11].
Differences in languages and cultures across the world 
have led to the translation of the EORTC QLQ-C30 and 
QLQ-BN20 into many different languages. The EORTC 
QLQ-C30 has been used in over 3000 studies to date and 
has been translated and approved in over 100 languages 
[12]. Although this includes Urdu, the national and offi-
cial language of Pakistan, the validation of the Urdu ver-
sion of the EORTC QLQ-C30 in a Pakistani population 
has to the best of our knowledge only been carried out 
in a cohort of 70 patients with hematologic malignan-
cies [13]. The EORTC QLQ-BN20 has been less widely 
translated and validated, and never before in Urdu in a 
Pakistani population of patients with PBT [12]. There 
is an increasing need to assess the QoL experienced by 
patients with PBTs in Pakistan using proven tools such as 
the EORTC QLQ-C30 and QLQ-BN20. Due to cultural 
differences and a sizeable percentage of patients with 
PBT being from lower socioeconomic and less educated 
backgrounds, the English versions of the EORTC QLQ-
C30 and QLQ-BN20 are of limited utility in a Pakistani 
setting. Moreover, although more than 10 different lan-
guages are spoken by the different cultural groups and 
ethnicities in Pakistan, Urdu is spoken and understood 
throughout the country. Thus, this study aimed to for-
mulate and validate an appropriately translated Urdu ver-
sion of the EORTC QLQ-C30 and QLQ-BN20 amongst 
patients with PBT in Pakistan. In addition, this study also 




The two tools validated in this study were the European 
Organization for Research and Treatment of Cancer 
Plain language summary 
Quality of life (QoL) is an important facet of well-being for patients with primary brain tumors (PBTs), as these individu-
als face significant distress during the course of their illness and treatment. It is important to have valid and reliable 
tools to accurately measure the QoL of patients with PBTs. The EORTC QLQ-C30 (European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire) and its brain tumor-specific module EORTC QLQ-BN20 (EORTC 
QLQ-Brain Neoplasms 20) are exactly that.
However, the use of the EORTC QLQ-C30 and QLQ-BN20 is limited in Pakistan, where the national language is Urdu, 
and the majority of patients are of low socioeconomic backgrounds. Since no Urdu translations of the EORTC QLQ-
C30 and QLQ-BN20 exist, we aimed to translate and validate these tools to enable their applicability in Pakistan.
The Urdu versions of the EORTC QLQ-C30 and QLQ-BN20 demonstrated good validity amongst patients with PBTs. 
Thus, our study confirms the EORTC QLQ-C30 and QLQ-BN20 as valuable clinical tools for the measurement of QoL in 
primary brain tumors patients within the linguistic, cultural and socioeconomic context of Pakistan.
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Page 3 of 12Zahid et al. J Patient Rep Outcomes            (2021) 5:79  
Quality of Life Questionnaire (EORTC QLQ-C30) and 
the EORTC QLQ-Brain Neoplasms 20 (EORTC QLQ-
BN20). Permission was obtained from the EORTC for 
the translation and validation of both tools. In addition, 
to explore the correlation of QoL with resilience, depres-
sion, and anxiety, two additional tools were included in 
the survey: Wagnild and Young’s Resilience Scale (RS-
14) and Hospital Anxiety and Depression Scale (HADS). 
Thus, the final survey instrument consisted of a section 
on demographic and clinical characteristics, followed by 
the EORTC QLQ-C30, EORTC QLQ-BN20, RS-14 and 
HADS:
• EORTC QLQ-C30: A 30-item QoL measure for 
patients with cancer. The tool comprises five multi-
item functional scales (physical, role, cognitive, emo-
tional, and social), three symptom scales (fatigue, 
pain, and nausea and vomiting), a global health and 
QoL scale, and single items for measurement of other 
symptoms frequently experienced by cancer patients 
(such as dyspnea, appetite loss, sleep disturbance, 
constipation, and diarrhea), in addition to the per-
ceived financial impact of the disease and treatment 
[10]. All items are scored using a 4-point Likert scale 
(1: ‘not at all’; to 4: ‘very much’), except for two items 
in the global health/QoL scale which instead employ 
modified 7-point linear analog scales [14]. The func-
tioning and global QoL subscales are scored ranging 
from 0 to 100, where higher scores imply favorable 
conditions. However, while symptom subscales are 
also scored ranging from 0 to 100, higher scores in 
these subscales imply greater symptoms i.e., unfa-
vorable conditions.
• EORTC QLQ-BN20: A 20-item QoL measure specifi-
cally for patients with primary brain neoplasms [11]. 
The tool comprises four domains all relevant to the 
disease (future uncertainty, visual disorder, motor 
dysfunction, and communication deficit), in addition 
to seven single items (headaches, seizures, drowsi-
ness, hair loss, itchy skin, weakness of legs, bladder 
control). All items are scored using a 4-point Likert 
scale (1: ‘not at all’; to 4: ‘very much’) and are then 
linearly converted to a 0–100 scale, where a higher 
score implies unfavorable conditions.
• RS-14: A 14-item measure of five core characteristics 
of resilience (purposeful life, perseverance, equanim-
ity, self-reliance and existential loneliness) that uses 
a 7-point Likert Scale to calculate an aggregate score 
for resilience [15]. The higher the score on the RS-14, 
the higher the resilience. The validated Urdu version 
of RS-14 was used, which has an acceptable Cron-
bach’s alpha of 0.763 [16]. We re-verified the inter-
nal consistency of the translated RS-14 and found a 
Cronbach’s alpha of 0.903, demonstrating excellent 
internal consistency of the RS-14 in the current pop-
ulation of brain tumor patients.
• Hospital Anxiety and Depression Scale (HADS): A 
14-item tool using a 4-point ordinal scale to meas-
ure depression and anxiety. The lower the score on 
the HADS, the more favorable the outcome. The 
Urdu version of the HADS [17] was used. The Urdu 
version of the HADS has been validated in pregnant 
females, and has been found to have an overall Cron-
bach’s alpha of 0.84 [18]. The Cronbach’s alpha for 
the depression and anxiety subscales were 0.64 and 
0.82, respectively [18]. We re-evaluated the internal 
consistency for our sample. While the tool’s overall 
internal consistency (Cronbach’s alpha: 0.89) and that 
of the anxiety subscale (Cronbach’s alpha: 0.81) were 
comparable to the previously reported values, the 
Cronbach’s alpha for the depression scale amongst 
our sample (Cronbach’s alpha: 0.86) was higher than 
previously reported.
Translation of study tools and pilot testing
For purpose of validation in Urdu, the EORTC QLQ-
C30 and QLQ-BN20 underwent a translation process in 
accordance with EORTC standards [19] and COSMIN 
Study Design Checklist for Patient-reported Outcome 
Measure Instruments [20]. Two translators initially 
translated the English versions of the EORTC QLQ-C30 
and QLQ-BN20 into Urdu independently. Both transla-
tors involved in the forward translation were bilingual, 
with native proficiency in Urdu and full professional 
proficiency in English, and with more than 7 years of 
experience in translation of healthcare-related surveys. 
To reduce the risks of bias and to identify subtle dis-
crepancies, one of the translators was aware of the con-
structs that the tools were intended to measure, while 
the other translator was naïve to the intended purpose of 
the tools. One consolidated Urdu version was then pro-
duced, which subsequently underwent backwards trans-
lation to English by two translators independently. Both 
translators involved in the backwards translation were 
native Urdu speakers with full professional proficiency in 
English, and were naïve to the intended purpose of the 
tools. A single consolidated backwards-translated Eng-
lish version of each tool was created and reviewed by the 
research team for consistency with the original English 
tools. Differences in the translation were then reviewed 
and settled in the presence of a third independent trans-
lator who was aware of the constructs measured by the 
tools. The difficulties encountered during the transla-
tion process are described in the Additional files 1 and 
2. The preliminary Urdu translated versions were pilot 
tested on 25 (i.e., 10% of calculated minimum required 
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sample size) brain tumor patients who were native Urdu 
speakers. This pilot testing, a form of linguistic validation 
of the comprehensibility of the tools, was performed in 
accordance with the guidelines published by the EORTC 
[21]. Prior to the administration of the tool via individual 
interviews, patients participating in the pilot testing were 
instructed to comment on whether any questions in the 
tool were difficult to understand, difficult to answer, con-
fusing, upsetting, or offensive. Patients were also asked to 
rate the comprehensibility of each item in the tools using 
a Likert scale of 1–4 (see “Content validity index”). No 
major areas of improvement were identified by partici-
pants during the pilot testing, and only a few minor revi-
sions were effected to produce a final Urdu translation of 
both tools. These final forms were included in the survey 
instrument of the current study.
Study setting
This survey was conducted over the period November 
2019 to May 2020 at the Aga Khan University Hospi-
tal (AKUH), which is a Joint Commission International 
Accreditation (JCIA-accredited) hospital in Karachi, 
Pakistan.
The institutional review board of AKUH granted ethi-
cal approval for this study (Reference Number: 5154-Sur-
ERC-17). The complete protocol of this study has been 
published by the authors [8].
Study subjects and sampling
Our target population was adult (≥ 18 years) patients 
treated for primary malignant brain tumors at AKUH. 
Patients were included if they were currently ≥ 4 weeks 
post-initiation of treatment, provided written informed 
consent for participation, and were residing in Pakistan 
for at least the past 3 months. The lattermost criterion 
was to ensure the validation of the EORTC QLQ-C30 
and QLQ-B20 tool was achieved while measuring QoL in 
the context and setting of Pakistan, as patients residing 
abroad may experience QoL different to their counter-
parts residing in Pakistan.
Exclusion criteria included patients with history of 
psychiatric illness or on prescription psychiatric medica-
tions, or with debilitating comorbidities such as stroke 
or renal failure. However, patients with comorbid hyper-
tension (HTN), type 2 diabetes mellitus (T2DM) or 
chronic obstructive pulmonary disease (COPD) were 
not excluded from the sample, as the prevalence of these 
comorbidities is high amongst the Pakistani population 
[22]. Moreover, these comorbidities are commonly seen 
in patients with brain tumors [23]. Thus, including such 
patients ensured a representative population.
Non-probability consecutive sampling was used for 
recruiting participants. Trained research assistants 
approached brain tumor patients visiting AKUH as per 
their scheduled appointments at the surgical/oncology 
clinics. Potential participants were screened for eligibility 
by the research assistants. After providing their informed 
consent, they were administered the EORTC QLQ-C30 
and QLQ-BN20 tools as part of a survey conducted as an 
interview by the research assistants. Although both the 
EORTC QLQ-C30 and QLQ-BN20 tools are generally 
self-administered, we opted to routinely administer them 
via interviews so as to include patients within our set-
ting who lacked the literacy to read (similar to Montaz-
eri et  al. in their Iranian translation and administration 
[24]). A minimum sample size of 250 was required. This 
was calculated using the one population mean formula, 
a standard deviation (SD) of 20, 5% level of significance 
with precision of 2.5, and by adjusting the sample size for 
10% rate of incomplete responses [8].
Content validity index
Content validation of the EORTC QLQ-C30 and QLQ-
BN20 tool was performed with accordance to the COS-
MIN Study Design Checklist for Patient-reported 
Outcome Measure Instruments [20]. Five experts (a psy-
chologist, epidemiologist, biostatistician, neurosurgeon, 
and mental health researcher) were asked to rate the rel-
evance of all items of both tools using a Likert scale of 
1–4. In addition, patients participating in the pilot testing 
were requested to rate the relevance and clarity (com-
prehensibility) of each item in the tools using a Likert 
scale of 1–4. However, the comprehensiveness of EORTC 
QLQ-C30 and QLQ-BN20 was not assessed from the 
professionals’ or patients’ perspective. Both tools used 
were pre-constructed and have been used in their cur-
rent form in studies globally, and the comprehensiveness 
of their content is well established. Content validity index 
(CVI) scores for clarity and relevance of the tools were 
calculated as described below in the Statistical Analysis 
section.
Statistical analysis
Data was analyzed using SPSS Statistics for Windows 
version 23.0 (IBM Corp., Armonk, N.Y., USA). Two 
members of the research team were involved in data 
analysis. Categorical variables were represented as fre-
quencies and percentages. Numerical variables were 
represented by mean and standard deviation or median 
and interquartile range. The Pearson correlation coeffi-
cients were calculated to determine the construct validity 
between EORCT QLQ-C30 and QLQ-BN20 with RS-14 
and HADS. Reliability was estimated using the Cron-
bach’s alpha coefficient, with a value ≥ 0.70 considered 
acceptable. Content validation index (CVI) was reported 
to determine the relevance and clarity of the content of 
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the tool. For each item, the score suggested by the raters 
was summed up and divided by the total number of raters 
to obtain an average score for each item. The sum of the 
average score of each item was further divided by the 
total number of items to obtain a CVI score ranging from 
0 to 1 (1 = perfect agreement; and 0 = no agreement). 
Interscale correlations were also calculated for both the 




A total of 255 patients with PBTs were approached for 
inclusion in this survey. However, five amongst these 
were ineligible (1 patient no longer resided in Pakistan 
and 4 patients had pre-existing psychiatric disorders), 
leaving a total of 250 participants in the final sample. 
Their mean age was 44 ± 0.83 years, and 68% were male. 
The most common mother tongue was Urdu (30.8%), 
with others including Sindhi (18.8%), Punjabi (14.8%) 
and Pushto (10.4%). However, every patient was able to 
understand and fluently converse in Urdu, with no lan-
guage barriers to administering the survey. The diagno-
ses of PBTs included glioma (46.8%) and meningioma 
(21.2%). Most participants had undergone tumor biopsy 
(78%). 9.6% patients reported receiving radiotherapy, 
4.4% chemotherapy, and 25.2% combination therapy, 
while 60.8% reported no adjuvant therapy (Table 1).
Internal consistency or reliability
Table  2 depicts the reliability of the EORTC QLQ-C30 
tool and QLQ-BN20 tool. The Cronbach alphas for the 
30 items of the QLQ-C30 and the 20 items of the QLQ-
BN20 were 0.860 and 0.880, respectively, indicating good 
internal consistency of both tools. The internal consist-
ency for the global health status scale of the QLQ-C30 
was also good (Cronbach’s alpha = 0.800; p < 0.001). 
The Cronbach’s alpha for the 15 items of the functional 
scale of the QLQ-30 tool was 0.74 (range: 0.630–0.830), 
indicating acceptable to good internal consistency (p < 
0.001). The overall internal consistency for the 11 items 
of the symptom scale of the QLQ-C30 was also good 
(Cronbach’s alpha 9 = 0.82 (range: 0.800–0.86); p < 
0.001). Lastly, the consistency of the four domains of the 
QLQ-BN20 demonstrated acceptable-to-good consist-
ency (Cronbach’s alpha range: 0.703–0.868).
Content validity
The expert-reported CVI scores for relevance of the 
Urdu version of the EORTC QLQ-C30 and QLQ-BN20 
tool were 0.96 and 0.95, respectively, indicating excellent 
agreement among the five experts. The patient-reported 
CVI scores for clarity and relevance of the Urdu version 
of the EORTC QLQ-C30 were 0.92 and 0.93, respectively. 
Table 1 Participant demographic characteristics and disease-
related factors
PKR, Pakistani Rupee; USD, US Dollars
Variables N = 250
N (%)/Median (IQR)























Monthly household income (PKR/USD)
No income 18 (7.2)
1000–25,000 ($6.04–$151) 40 (16.0)
25,000–40,000 ($151–$242) 26 (10.4)
40,000–80,000 ($242–$484) 69 (27.6)








Only biopsy 195 (78.0)
Only total resection 11 (4.4)
Multiple interventions 27 (10.8)





No adjuvant therapy 152 (60.8)
Treatment stage for brain tumor
On-going 138 (55.2)
Complete 112 (44.8)
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Similarly, the patient-reported CVI scores for clarity and 
relevance of the Urdu version of the QLQ-BN20 tool 
were 0.80 and 0.93, respectively. These results indicate 
good-to-excellent agreement among the 25 patients for 
clarity and relevance of both tools.
Construct validity
The correlation of QoL (as measured by EORTC QLQ-
C30 and QLQ-BN20) with resilience (RS-14) was 
assessed using Pearson correlation coefficients (Tables 3, 
4). We observed a significant moderate positive corre-
lation between global status of EORTC QLQ-C30 and 
resilience (r = 0.422; p value < 0.001). Similarly, there was 
a significant moderate positive correlation between the 
5 domains of the functional scale of EORTC QLQ-C30 
and resilience (r ranging from 0.462 to 0.570; p value < 
0.001). Lastly, there was a significant moderate negative 
correlation between future uncertainty and resilience 
(r = −0.473, p < 0.001).
When assessing the correlation between the EORCT 
QLQ-C30 and the QLQ-BN20 tool with depression 
and anxiety as measured using the HADS, we observed 
a significant moderate negative correlation between 
global status of EORTC QLQ-C30 with depression 
(r  =  −0.541; p <  0.001) and anxiety (r  =  −0.502; p 
< 0.001). Additionally, there was a significant moderate-
to-strong negative correlation between the 5 domains of 
the functional scales of the EORTC QLQ-C30 i.e., with 
both depression (r ranging from −0.467 to −0.688; p < 
0.001) and anxiety (r ranging from −0.276 to −0.704; p 
< 0.001). There was a strong positive correlation between 
future uncertainty and depression (r = 0.614, p < 0.001) 
and moderate correlation between future uncertainty and 
anxiety (r = 0.514, p < 0.001). The Pearson’s correlation 
coefficients for the EORTC QLQ-C30 and QLQ-BN20 
with the HADS are shown in Tables 3 and 4, respectively.
Inter‑scale correlation of EORTC QLQ‑C30 and EORTC 
QLQ‑BN20
When assessing inter-scale correlations of EORTC QLQ-
30, we observed a significant weak-to-moderate positive 
correlation between global QoL and the 5 functional 
domains (r ranging from 0.384 to 0.561; p < 0.001). We 
observed a significant moderate-to-strong positive cor-
relation (r ranging from 0.40 to 0.68; p  <  0.01) within 
the 5 functional domains of EORCT QLQ-30, with 
strongest correlation between physical and role func-
tioning (r =  0.600; p  <  0.001), physical and social func-
tioning (r = 0.631; p=0.001), role and social functioning 
(r = 0.680; p < 0.001).
Table 2 Internal consistency of EORTC QLQ-C30 (1A) and QLQ-BN20 (1B)
*Significant at p-value < 0.05 by reliability analysis
1A: QLQ‑C30
Cronbach’s alpha (p value)
Overall 0.86 (< 0.001*)
Global
Global status 0.80 (< 0.001*)
Functional
Physical functioning 0.83 (< 0.001*)
Role functioning 0.82 (< 0.001*)
Emotional functioning 0.75 (< 0.001*)
Cognitive functioning 0.63 (< 0.001*)
Social functioning 0.79 (< 0.001*)
Symptoms
Fatigue 0.36 (< 0.001*)
Nausea and vomiting 0.40 (< 0.001*)
Pain 0.46 (< 0.001*)
1B: QLQ‑BN20
Overall 0.88 (< 0.001)*
Future uncertainty 0.801 (< 0.001*)
Symptoms
Visual disorder 0.790 (< 0.001*)
Motor dysfunction 0.703 (< 0.001*)
Communication deficit 0.868 (< 0.001*)
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Moreover, a significant weak-to-strong negative cor-
relation was observed between 5 functional domains 
and 8 symptom domains of EORCT QLQ-30 (r ranging 
from −0.172 to −0.690; p <  0.01), with strongest cor-
relations between physical functioning and insomnia 
(r = −0.690; p < 0.001) and role functioning and insom-
nia (r = −0.641; p < 0.001). In addition, within the symp-
tom domains, the strong correlation was between fatigue 
and pain (r =0.602; p < 0.001).
When assessing inter-scale correlations of EORTC 
QLQ-BN20, we observed a significant weak-to-strong 
positive correlation of future uncertainty and 9 symptom 
domains (r ranging from 0.245 to 0.628; p < 0.001), with 
the strongest correlation between future uncertainty and 
drowsiness (r = 0.628; p < 0.001). The strongest correla-
tions within the symptom domains were between motor 
dysfunction and drowsiness (r = 0.605; p <  0.001) and 
Table 3 Correlation between QLQ-C30 with resilience, depression and anxiety (construct validity)
r = Pearson correlation coefficient
*Significant at p value < 0.05
QLQ C‑30 Resilience score Depression score Anxiety score
r (p value)
Global quality of life 0.422 (< 0.001)*  − 0.541 (< 0.001)*  − 0.502 (< 0.001)*
Functional
Physical functioning 0.570 (< 0.001)*  − 0.545 (< 0.001)*  − 0.276 (< 0.001)*
Role functioning 0.472 (< 0.001)*  − 0.542 (< 0.001)*  − 0.320 (< 0.001)*
Emotional functioning 0.462 (< 0.001)*  − 0.688 (< 0.001)*  − 0.704 (< 0.001)*
Cognitive functioning 0.504 (< 0.001)*  − 0.467 (< 0.001)*  − 0.293 (< 0.001)*
Social functioning 0.478 (< 0.001)*  − 0.490 (< 0.001)*  − 0.319 (< 0.001)*
Symptoms
Fatigue  − 0.075 (0.236) 0.298 (< 0.001)* 0.327 (< 0.001)*
Nausea and vomiting  − 0.158 (0.012)* 0.243 (< 0.001)* 0.275 (< 0.001)*
Pain  − 0.191 (0.002)* 0.412 (< 0.001)* 0.433 (< 0.001)*
Dyspnea  − 0.172 (0.006)* 0.334 (< 0.001)* 0.332 (< 0.001)*
Insomnia  − 0.508 (< 0.001)* 0.463 (< 0.001)* 0.267 (< 0.001)*
Appetite loss  − 0.305 (< 0.001)* 0.554 (< 0.001)* 0.500 (< 0.001)*
Constipation  − 0.179 (0.004)* 0.119 (0.061) 0.071 (0.261)
Diarrhea  − 0.050 (0.429) 0.162 (0.01)* 0.036 (0.576)
Financial difficulties  − 0.314 (< 0.001)*  − 0.266 (< 0.001)* 0.186 (0.003)*
Table 4 Correlation between QLQ-BN20 with resilience, depression and anxiety (construct validity)
r = Pearson correlation coefficient
*Significant at p value < 0.05
QLQ‑BN20 Resilience score Depression score Anxiety score
Future uncertainty  − 0.473 (< 0.001)* 0.614 (< 0.001)* 0.514 (< 0.001)*
Symptoms
Visual disorder  − 0.347 (< 0.001)* 0.277 (< 0.001)* 0.139 (0.029)*
Motor dysfunction  − 0.571 (< 0.001)* 0.458 (< 0.001)* 0.209 (0.001)*
Communication deficit  − 0.514 (< 0.001)* 0.425 (< 0.001)* 0.211 (0.001)*
Headache  − 0.121 (0.054) 0.236 (< 0.001)* 0.246 (< 0.001)*
Seizures  − 0.168 (0.008)* 0.149 (0.018)* 0.014  (0.822)
Drowsiness  − 0.408 (< 0.001)* 0.442 (< 0.001)* 0.262 (< 0.001)*
Hair loss  − 0.196 (0.002)* 0.144  (0.022)* 0.138 (0.029)*
Itchy skin  − 0.166 (0.008) * 0.185 (0.003)* 0.145 (0.022)*
Weakness in leg  − 0.478 (< 0.001)* 0.437 (< 0.001)* 0.284 (< 0.001)*
Bladder control  − 0.218 (0.001)* 0.277 (< 0.001)* 0.220 (< 0.001)*
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motor dysfunction and weakness in leg (r =  0.683; p < 
0.001).
The interscale Pearson’s correlation coefficients for 
EORTC QLQ-C30 and QLQ-BN20 are shown in Tables 5 
and 6, respectively.
Discussion
Though health related QoL is an increasingly important 
outcome in the management of patients with malignant 
PBTs, it is challenging to measure QoL of patients with 
PBTs in Pakistan due to the lack of specific tools avail-
able in Urdu. In this regard, we attempted to translate 
and validate the EORTC QLQ-C30 and QLQ-BN20 in 
Urdu, the national and official language of Pakistan, to 
provide a valuable tool for the measurement of QoL of 
patients with PBTs in a clinical setting. With overall 
high internal consistency (Cronbach’s alpha: 0.86 and 
0.88, respectively), and content validity index scores for 
patient-reported clarity (0.92 and 0.80, respectively) and 
expert-reported relevance (0.96 and 0.95, respectively), 
the Urdu versions of the EORTC QLQ-C30 and QLQ-
BN20 tools displayed good validity in patients with PBTs 
in our study.
The overall experience of the translation and valida-
tion process of the EORTC QLQ-C30 and QLQ-BN20 in 
Urdu was relatively straightforward. The translations in 
Urdu were able to accurately convey the intended Eng-
lish equivalents, and none of the patients had any major 
issues with understanding the final Urdu version of either 
tool. This was encouraging, as the Urdu translations of 
both tools displayed high content validity for clarity and 
relevance. Moreover, as both tools were administered via 
interview as opposed to self-administration, our results 
also demonstrate the undiminished value of the EORTC 
QLQ-C30 and QLQ-BN20 tools in populations of LMICs 
where literacy may be low [24]. This study was conducted 
in Karachi, the largest city of the country, and home to 
all major ethnicities living in Pakistan. In addition, the 
Aga Khan University Hospital (AKUH) is one of the larg-
est private quaternary care hospitals catering to diverse 
ethnic and socioeconomic groups within Karachi. The 
patients with PBTs in our sample represented heterog-
enous ethnicities and socioeconomic strata from within 
Pakistan, as evidenced by the diversity of mother tongues 
(Urdu: 30.8%, Sindhi: 18.8%, Punjabi: 14.8%, Pushto: 
10.4%, Saraiki: 4.4%, Balochi 4%, and Hindko: 2.4%) and 
distribution of monthly family incomes. The diversity 
in patients’ demographics in our study strengthens the 
generalizability and utility of the Urdu translation of the 
EORTC QLQ-C30 and QLQ-BN20 as tools for measur-
ing QoL within the sociocultural context of Pakistan.
The internal consistency of the Urdu version of the 
EORTC QLQ-C30 was high for the overall tool (Cron-
bach’s alpha: 0.86) and the global scale (0.80). The only 
other study reporting translation and validation of the 
EORTC QLQ-C30 in Urdu that we were able to find also 
reported a high Cronbach’s alpha of 0.82 for the overall 
tool [13].
Moreover, internal consistency was within minimum-
to-ideal ranges (0.75–0.83) for most functional subscales 
in the current study. The exception was the subscale for 
cognitive functioning (0.63). The relatively low inter-
nal consistency of the cognitive functioning subscale 
has been observed in previous translation and valida-
tion studies in Korean (0.60) [25], Chinese (0.45) [26] 
and Japanese (0.63) [27], and also in validation studies 
Table 6 Interscale correlations of EORCT QLQ-BN20
FU, future uncertainty; VD, visual disorder; M, motor dysfunction; CD, communication deficit; HA, headache; SZ, seizures; DS, drowsiness; HL, hair loss; IS, itchy skin; WL, 
weakness in leg; BC, bladder control
+ Significant at p < 0.05
*Significant at p < 0.01
FU VD M CD HA SZ DS HL IS WL BC
FU 1 0.402* 0.458* 0.346* 0.280* 0.346* 0.628* 0.245* 0.109 0.385* 0.358*
VD 0.402* 1 0.372* 0.467* 0.202* 0.167* 0.441* 0.216* 0.077 0.256* 0.288*
MD 0.458* 0.372* 1 0.568* 0.183* 0.191* 0.605* 0.203* 0.137+ 0.683* 0.400*
CD 0.346* 0.467* 0.568* 1 0.092 0.141+ 0.450* 0.046 0.235* 0.366* 0.187*
HA 0.280* 0.202* 0.183* 0.092 1 0.085 0.259* 0.134+ 0.057 0.153+ (0.258*
SZ 0.346* 0.167* 0.191* 0.141+ 0.085 1 0.254*  − 0.052  − 0.083 0.278* 0.024
DS 0.628* 0.441* 0.605* 0.450* 0.259* 0.254* 1 0.221* 0.176* 0.453* 0.348*
HL 0.245* 0.216* 0.203* 0.046 0.134  − 0.052 0.221* 1 0.325* 0.128+ 0.485*
IS 0.109* 0.077 0.137+ 0.235* 0.057  − 0.083 0.176* 0.176* 1 0.149+ 0.242*
WL 0.385* 0.256* 0.683* 0.366* 0.153+ 0.278* 0.453* 0.453* 0.149+ 1 0.350*
BC 0.358* 0.288* 0.400* 0.187* 0.258* 0.024 0.348* 0.348* 0.242* 0.350* 1
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of the original version of the EORTC QLQ-C30 by Aar-
onson et  al. (0.54) [10], Bjordal et  al. (0.28) [28], Osoba 
et al. (0.56) [29], and Ringdal et al. (0.65) [30]. Thus, our 
study also corroborates findings in existing literature 
which suggest that the cognitive functioning subscale of 
the EORTC QLQ-C30 has low reliability. This may be 
because memory and concentration are different aspects 
of cognitive functioning [26], although it is clinically 
more useful to measure cognitive functioning as a single 
construct. Lastly, in our sample, the consistency of the 
overall tool (0.88) and the four domains of symptoms in 
the QLQ-BN20 also demonstrated above minimum psy-
chometric consistency (0.703–0.868). These ranges are 
similar to translation and validation studies conducted in 
other languages, including Persian (0.740–0.890) [31] and 
Chinese (0.753–0.869) [32]. Moreover, a review of the 
internal consistencies of the different translations of the 
EORTC QLQ-BN20 reviewed an overall range of internal 
consistency of the four subscales ranging from 0.71–0.90 
[33]. Our results thus align with previous evidence and 
confirm the reliability of the Urdu version of the EORTC 
QLQ-BN20 in a Pakistani setting.
Lastly, inter-scale correlations for the Urdu version of 
the EORTC QLQ-C30 and QLQ-BN20 were significant 
in the expected directions, and similar to those seen pre-
vious studies validating the Iranian and Korean versions 
[24, 25].
The Urdu versions of both the EORTC QLQ-C30 and 
QLQ-BN20 tools also demonstrated acceptable construct 
validity, with the global quality of life domain show-
ing significant positive correlations with resilience (r = 
0.422), and significant negative correlations with depres-
sion (r = −0.541) and anxiety (r = −0.502). Previous 
studies have also reported similar positive correlations 
between QoL and resilience [34, 35] and similar negative 
correlations between QoL and depression and anxiety in 
cancer patients [36, 37]. In addition, the Hindi translation 
of the EORTC QLQ-BN20 has also demonstrated signifi-
cant correlations with depression and anxiety as meas-
ured by HADS [38].
The Urdu translations of the EORTC QLQ-C30 and 
QLQ-BN20 hold considerable clinical relevance for the 
management of patients with malignant PBTs in Paki-
stan. Keeping in mind cultural differences in Pakistan 
and that most patients with PBT belong from less edu-
cated backgrounds, it is crucial to have tools that pro-
vide valid assessments of QoL in a Pakistani population. 
Urdu, being the national and official language, is spo-
ken and understood throughout the country. Thus, our 
translation and validation of the EORTC QLQ-C30 and 
QLQ-BN20 provides a comprehensive, valid, and reliable 
method for the measurement of QoL in patients with 
malignant PBTs in Pakistan. Assessment of QoL may be 
incorporated into the routine management of patients 
with malignant PBTs in Pakistan, particularly in holistic 
goal setting, prognostication, and monitoring the impact 
of disease and therapy. In addition, the tools also provide 
a much-needed measure of patient-reported outcomes in 
clinical cancer research in Pakistan.
Our study has a few limitations. Firstly, we did not 
perform test-retest analysis to investigate stability. Addi-
tionally, the cross-sectional nature of the study does not 
capture changing relationships between QoL, resilience, 
depression, and anxiety. However, our study is the first 
validating the Urdu versions of EORTC QLQ-BN20 and 
QLQ-C30 in a sample of patients with malignant PBTs in 
Pakistan. Our results provides the preliminary base for 
further psychometric evaluation.
Conclusion
Our study performed the translation of the EORTC 
QLQ-C30 and QLQ-BN20 to Urdu as per EORTC guide-
lines. The Urdu versions of the EORTC QLQ-C30 and 
QLQ-BN20 demonstrated good validity amongst patients 
with primary brain tumors. Thus, our study confirms 
the EORTC QLQ-C30 and QLQ-BN20 as valuable clini-
cal tools for the measurement of QoL in primary brain 
tumors patients within the cultural and socioeconomic 
context of Pakistan.
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